"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 |
| 1996 | 2 | 0 | 2 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 2 | 4 |
| 1999 | 4 | 1 | 5 |
| 2000 | 2 | 3 | 5 |
| 2001 | 2 | 1 | 3 |
| 2002 | 3 | 1 | 4 |
| 2003 | 5 | 7 | 12 |
| 2004 | 7 | 5 | 12 |
| 2005 | 5 | 4 | 9 |
| 2006 | 9 | 2 | 11 |
| 2007 | 10 | 8 | 18 |
| 2008 | 6 | 2 | 8 |
| 2009 | 7 | 5 | 12 |
| 2010 | 10 | 10 | 20 |
| 2011 | 12 | 10 | 22 |
| 2012 | 12 | 8 | 20 |
| 2013 | 8 | 8 | 16 |
| 2014 | 19 | 3 | 22 |
| 2015 | 17 | 15 | 32 |
| 2016 | 16 | 10 | 26 |
| 2017 | 11 | 5 | 16 |
| 2018 | 6 | 12 | 18 |
| 2019 | 11 | 10 | 21 |
| 2020 | 10 | 7 | 17 |
| 2021 | 10 | 7 | 17 |
| 2022 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Beyond glyco-proteomics-Understanding the role of genetics in cancer biomarkers. Adv Cancer Res. 2023; 157:57-81.
-
A digital assay for programmed death-ligand 1 (22C3) quantification combined with immune cell recognition algorithms in non-small cell lung cancer. Sci Rep. 2022 06 13; 12(1):9745.
-
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. J Transl Med. 2022 06 07; 20(1):257.
-
Predictive value of collagen in cancer. Adv Cancer Res. 2022; 154:15-45.
-
Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat Med. 2022 01; 28(1):125-135.
-
E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects. JCI Insight. 2021 12 22; 6(24).
-
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 12 21; 12(1):7349.
-
Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists. Cancer Med. 2022 01; 11(2):530-538.
-
Targeted Therapy for BRAF Mutant Brain Tumors. Curr Treat Options Oncol. 2021 10 06; 22(11):105.
-
Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. Cancer Res. 2021 12 01; 81(23):5818-5832.